Intra-Cellular Therapies (NASDAQ:ITCI) Posts Earnings Results, Misses Expectations By $0.08 EPS

Intra-Cellular Therapies (NASDAQ:ITCI) issued its earnings results on Friday. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08), Zacks reports. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%.

Intra-Cellular Therapies Stock Up 0.1 %

ITCI traded up $0.07 during trading on Friday, reaching $128.61. 562,293 shares of the company were exchanged, compared to its average volume of 4,171,555. The company’s 50-day moving average is $109.36 and its two-hundred day moving average is $89.29. The company has a market cap of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72. Intra-Cellular Therapies has a 12-month low of $62.78 and a 12-month high of $128.77.

Insiders Place Their Bets

In related news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ITCI shares. JPMorgan Chase & Co. raised their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Piper Sandler reissued a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price target for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Finally, Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $103.62.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.